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After years of controversy, there is no doubt that poor
glycemic control is the main and fundamental basis for de-
velopment of albuminuria and renal lesions in diabetes.
Blood pressure elevation usually comes secondarily, at
least in type 1 diabetes, but in type 2 diabetes, microal-
buminuria and some blood pressure elevation may be
present already with the diagnosis of diabetes, along with
dyslipidemia. Genetic factors have been proposed to be
important, and so far, analysis of genotypes has no place
in clinical practice [1–3].
In many studies, microalbuminuria along with blood
pressure elevation, even minor, is crucial to the later
outcome of patients, and also regarding strategy for
treatment. When microalbuminuria is found along with
increased blood pressure, the prognosis is even poorer
than with only one of these abnormalities present in the
patients. Indeed, high blood pressure may be part of
the family history of some patients and, therefore, again
emerging as a familiar risk factor, although only relevant
to few patients.
Microalbuminuria in type 1 and type 2 diabetes
Albuminuria is a continuum not only in its range, but
also in time. Initially, all patients with type 1 diabetes will
have a urinary albumin excretion rate (UAER)in the nor-
mal range unless they have ketosis. In type 2 diabetes, the
disease may have been present for several years at clinical
presentation, so patients may also present with microal-
buminuria due to elevated blood pressure along with poor
glycemic control. This is in contrast to patients with type
1 diabetes, where microalbuminuria is not found in the
early years, although it may be present in cases of poor
metabolic control, which may be a reversible abnormality.
Several studies have been conducted on the significance
of upper-normal albuminuria, which certainly represents
a risk factor [1].
Key words: blood pressure lowering, blood glucose normalization.
C© 2004 by the International Society of Nephrology
Hyperfiltration precedes microalbuminuria, an abnor-
mality that can be ameliorated by better metabolic con-
trol [3].
Microalbuminuria and mortality
In a follow-up study first communicated in 1983 and
1984, it was shown that microalbuminuria in type 2 dia-
betes is strongly predictive of an increased mortality. This
observation has since been confirmed in numerous stud-
ies. It also seems to be a strong, or even the strongest,
overall predictor of mortality, even in nondiabetic
population-based studies. Other factors that could be
associated with poor prognosis include continued long-
term hyperglycemia and high blood pressure. Interest-
ingly, poor metabolic control predicts microalbuminuria
and could also be a risk factor for its progression, whereas
high blood pressure can be more important in more ad-
vanced disease.
New studies have shown structural abnormalities in pa-
tients with type 2 diabetes and microalbuminuria. Among
the many risk factors analyzed, hyperglycemia and hy-
pertension seem to be of particular importance, as docu-
mented in initial studies on the relevance of higher UAE
rates in relation to other risk factors. It again appears that
there is a requirement for two risk factors: hyperglycemia
and high blood pressure factors must combine to produce
a clinically important disease. Since microalbuminuria in
type 2 diabetes is a better predictor of cardiovascular
than of microvascular disease, other macrovascular dis-
ease factors must be taken into consideration. Microal-
buminuria as a predictor for early mortality was recently
confirmed in a United States follow-up study where pa-
tients with a risk of retinopathy were examined. Simi-
lar observations are now available both for the U.S. and
Europe, including the UKPDS.
Long-term studies in T1 DM
The very long-term prognostic significance of microal-
buminuria and blood pressure variables for all-cause mor-
tality in type 1 diabetes is now being clarified. In 1977,
272 patients were identified through outpatient clinics
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Table 1. Type 1 diabetes prediction of worsening nephropathy
Publication
Mogensen CE et al, N
Engl J Med 1984; 311:
89–93 [6]
Diabetes Control and
Complications Trial.
N Engl J Med 2000;
342: 381–389 [10]
Initial micro 14 patients 64 patients
% to proteinuria 8.5%/year 8%/year a (conv.
control)
a2% with intensive therapy.
Table 2. Data on long-term follow-up in type 1 diabetic patients
Baseline Baseline 25-year RR vs.
Urinary blood pulse total background
albumin pressure pressure mortality population
<20 mg/L 130/82 48 29% (58/202) 2.3
20–200 mg/L 136/86 50 52% (23/44) 5.8
>200 mg/L 154/98 57 78% (18/23) 13.3
P value <0.001/<0.001 0.02 <0.001 <0.001
and general practitioners related to our center. The co-
hort constituted a representative sample of adult type
1 diabetic patients in Aarhus County. Inclusion criteria
were age 15 years or over (mean 33.9 ± 12.8) and du-
ration of diabetes 5 years or more (mean 18.0 ± 10.5).
Urinary albumin concentration (UAC), blood pressure,
presence of macrovascular disease, degree of retinopathy,
a composite measure for glycemic control, s-creatinine,
s-cholesterol, and smoking habits (pack years) were de-
termined. Only three patients were lost to follow-up. All-
cause mortality was 37% (99/269) over 25 years for the
whole group. As indicated in Table 2, baseline blood pres-
sure and pulse pressure increased significantly with in-
creasing albuminuria levels, as did total mortality over
25 years.
Cox multiple regression analysis (age-stratified) iden-
tified the following significant independent predictors of
all-cause mortality: microalbuminuria [RR 2.8; 95% CI
(1.5–5.2)], duration of diabetes [1.6 per 10 years (1.1–
2.3)], macrovascular disease at baseline [1.9 (1.1–3.79)],
smoking [1.9 (1.1–3.3)], glycemic control [2.3 (1.1–4.7)],
and pulse pressure [2.8 (1.3–6.3)]. Systolic, diastolic, and
mean BP was excluded from the model as was gender,
s-cholesterol, s-creatinine, and retinopathy. Mortality in
patients with UAC 20 to 200 mg/L was significantly in-
creased compared with patients with UAC <20 mg/L
(P < 0.001) and similar in patients with short (<16 years)
and long (>16 years) duration (P = 0.9, age-corrected).
For comparison, age-specific, sex-specific, and calen-
dar year–specific mortality rates were obtained from the
Danish Institute of Epidemiology. As indicated in the
Table, relative risk (RR) for total mortality was signifi-
cantly increased in the diabetic patients versus the back-
ground population.
This long-term study documents that abnormally in-
creased urinary albumin concentration, pulse pressure,
glycemic control, and smoking, all potentially modifiable
risk factors, are important predictors of increased mor-
tality in type 1 diabetes.
CONCLUSION
Microalbuminuria is part of a dangerous network asso-
ciated with many adverse factors. This means that we can
talk about a ‘microalbuminuric syndrome’ also in type 2
diabetes.
Microalbuminuria is associated with significant
glomerular pathology and increased renal, as well as
cardiovascular risks. There are many associated systemic
alterations that are amenable to effective treatment.
Recent strong evidence supports the benefit of inter-
vention at the phase of microalbuminuria, in type 1
diabetes in particular. In type 2 diabetes, treatment of
those with microalbuminuria remains of equally great
importance. It remains to be seen whether treatment of
at-risk patients with type 2 diabetes (and type 1) and a
normal UAE rate is as cost effective and beneficial as
treatment of patients with microalbuminuria. Combined
normoglycemia and low blood pressure are key elements
in the prevention of micro- and macrovascular disease in
diabetes along with statin treatment [4].
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